Pharvaris (NASDAQ:PHVS - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings data on Monday, April 7th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.06. On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Pharvaris Price Performance
NASDAQ:PHVS traded down $0.05 during mid-day trading on Friday, reaching $16.99. The company's stock had a trading volume of 15,489 shares, compared to its average volume of 73,890. The stock has a market cap of $888.41 million, a P/E ratio of -6.07 and a beta of -2.85. The company's fifty day simple moving average is $15.27 and its two-hundred day simple moving average is $17.89. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50.
Analyst Ratings Changes
Several equities research analysts recently issued reports on PHVS shares. JMP Securities raised their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st. Cantor Fitzgerald assumed coverage on Pharvaris in a report on Tuesday, April 29th. They set an "overweight" rating and a $28.00 price objective for the company.
Get Our Latest Research Report on Pharvaris
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
